A WORD FROM OUR CHIEF SCIENTIFIC OFFICER

Dear FAPI Community, 

For our first newsletter of 2025, I am happy to share that things are off to a roaring start on the FAPI front.

But first – a final highlight of 2024 was the activation of [18F]FAPI-74 production at now FIVE sites in SOFIE’s network – Totowa, NJ; Gilroy, CA; Romeoville, IL; Sanford, FL, and Cleveland, OH.  This growth in FAPI-74 manufacturing capability uniquely positions us to support our upcoming [18F]FAPI-74 clinical studies and academic investigator-initiated studies, in addition to companion use of [18F]FAPI-74 in Pharma collaborations.   Additional sites are planned for FAPI-74 manufacturing in 2025 so be sure to follow SOFIE’s LinkedIn account for the latest.

We reached a major milestone in February with the completion of recruitment for SOFIE’s [18F]FAPI-74 Phase 2 clinical trials. We are currently performing data analysis and behind the scenes planning for Phase 3 is well underway.

On Wednesday, May 14, I will be speaking at PEGS Boston on “[18F]FAPI-74 PET in Gastrointestinal Cancers – Addressing an Unmet Need”.  I hope to see you there in person or virtually.

Please share your feedback on how this newsletter can better serve you. We want to hear from you!

Sherly Mosessian, Ph.D.

– Sherly Mosessian, Ph.D., Chief Scientific Officer

FAPI-74 CLINICAL DEVELOPMENT UPDATE

FAPI Pipeline Winter 2025

PUBLICATION HIGHLIGHTS

Each newsletter will feature recent FAPI publications.

Spatial FAP Expression as Detected by 68 Ga-FAPI-46 Identifies Myofibroblasts Beyond the Infarct Scar After Reperfusion

Spatial FAP Expression as Detected by 68 Ga-FAPI-46 Identifies Myofibroblasts Beyond the Infarct Scar After Reperfusion

Mol Imaging Biol. 2025 Mar 3

Head-to-head comparison of 18F-FDG and 68Ga-FAPI PET/CT in common gynecological malignancies

Head-to-head comparison of 18F-FDG and 68Ga-FAPI PET/CT in common gynecological malignancies

Cancer Imaging. 2025 Feb 28

Discrimination between Inflammatory and Fibrotic Activity in Crohn's Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging

Discrimination between Inflammatory and Fibrotic Activity in Crohn’s Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging

Visc Med. 2025 Feb

FAPI OUTREACH PROGRAM

Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program

SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.

*GE Healthcare licensed products and regions are accepting new applications.

Copyright 2025 SOFIE CO. / ITHERANOSTICS INC. (21000 Atlantic Blvd. Suite 730  Dulles, VA  20166) all rights reserved.  The text or images in the newsletter may not be copied or distributed without prior permission of SOFIE. The SOFIE logo is a registered trademark of SOFIE CO. / ITHERANOSTICS INC., in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners. You have received this mail because you have subscribed for a newsletter at www.sofie.com or because you are an existing client or partner of SOFIE. If you no longer wish to receive these emails, click here to opt out.  This newsletter is meant to serve as an informational document as a service to our customers. The content or material provided is for informational purposes only and should and should not be construed as medical, legal, financial, investment, or other professional advice or opinion. SOFIE does not offer personalized medical advice or patient-specific treatment advice.